
Cutting out alcohol and medicating sooner could prevent 'silent killer,' experts say
Leading health groups say it's best to act sooner rather than later to prevent long-term damage — and they also recommend cutting out alcohol.
The American Heart Association (AHA) and the American College of Cardiology (ACC) teamed up with 11 other organizations to release new guidelines, published Aug. 14 in the American Heart Association's peer-reviewed journals Circulation and Hypertension, as well as in JACC, the flagship journal of the American College of Cardiology.
The new recommendations, which were refined through a rigorous peer-review process, represent the first major blood pressure update since 2017.
The guidelines detail how doctors tackle high blood pressure and how people can take steps to manage their own, with a focus on prevention, early treatment and protection of both heart and brain health.
"High blood pressure is the most prevalent and No. 1 modifiable risk factor for the development of cardiovascular diseases," Daniel W. Jones, M.D., chair of the guideline writing committee and professor emeritus of the University of Mississippi School of Medicine in Jackson, Mississippi, told Fox News Digital.
"Members of the writing committee have been monitoring new evidence continually since the last guideline published in 2017," he added.
Instead of using one-size-fits-all charts, the new approach focuses on the PREVENT (Preventing Risk of cardiovascular disease EVENTs) method, a tool that calculates a person's 10- and 30-year risk of heart attack or stroke.
In addition to blood pressure, it also considers cholesterol, kidney health, metabolic issues and geographical location.
The guidelines also urge doctors to act earlier. That could mean prescribing medication sooner or tapping into newer options like GLP-1 drugs for certain patients.
Another new recommendation was to cut out alcohol — a change from the prior guidance for people to limit consumption.
"We put forward the ideal as abstinence, and for those who choose to drink, less than one for women and less than two for men."
"A lot of people enjoy drinking, but because the evidence is there, we want you to make an informed decision," Jones said.
"There's a lot of individual variability with the relationship between alcohol and blood pressure, but we put forward the ideal as abstinence, and for those who choose to drink, less than one for women and less than two for men."
Jones called the new alcohol guidance one of the two "most notable changes in the 2025 guidelines," along with reducing sodium intake from 2300 mg a day to 1500 mg a day.
The experts also spotlighted the need to manage blood pressure during pregnancy to protect mothers and babies.
Some of the prior standards still apply, like managing stress through exercise and maintaining a healthy weight, with a goal of at least a 5% reduction in body weight in adults who are overweight or obese.
Nutrition remains a major factor, with recommendations to eat a healthy diet high in vegetables, fruits, whole grains, legumes, nuts and seeds, and low-fat or nonfat dairy, as well as lean meats and poultry, fish and non-tropical oils.
For more Health articles, visit www.foxnews.com/health
These habits, combined with earlier medical intervention when needed, could dramatically reduce long-term complications, experts say.
The blood pressure criteria remain the same as the 2017 guidelines, as seen in the chart below.
Research shows that controlling blood pressure earlier in life can also help prevent dementia and preserve brain health.
"There is now more clear and robust evidence that intensive lowering of blood pressure reduces the risk of cognitive decline and dementia," Jones added.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

Yahoo
42 minutes ago
- Yahoo
Viking Therapeutics stock falls 37% on high dropout rate in obesity trial
-- Viking Therapeutics (NASDAQ:VKTX) stock plunged as much as 37% Tuesday after revealing results from its Phase 2 VENTURE-Oral Dosing trial for its oral obesity treatment, while Eli Lilly (NYSE:LLY) shares gained 1.5% as analysts pointed to competitive advantages. The trial demonstrated that Viking's oral tablet formulation of VK2735, a dual GLP-1 and GIP receptor agonist, met its primary endpoint with patients losing up to 12.2% of body weight after 13 weeks compared to 1.3% for placebo. Despite the weight loss efficacy, the 28% treatment discontinuation rate among patients receiving VK2735 versus 18% for placebo raised significant concerns among investors and analysts. Mizuho analyst Jared Holz highlighted competitive disadvantages compared to Eli Lilly's offerings: "Data look inferior to LLY on almost all metrics and the thing to consider here is that patients discontinued at such a high rate over 13-weeks vs. LLY in the mid 20% range --- but over 72-weeks; A much longer trial, and therefor LLY looks far better head-to-head. This probably shutters hope for VKTX a bigtime player in the oral obesity market over the near to medium term." JPMorgan (NYSE:JPM) analyst Hardik Parikh offered a more balanced view, noting, "In 13 weeks, the three highest-dosing arms of 60/90/120mg showed avg pbo-adj weight loss of ~7.5%, 10%, 11%, which we think is very strong compared with other orals in development. Tolerability overall was manageable, but it was worse than we expected based on the ph1 performance." Parikh added that while the adverse event profile wasn't as clean as in Phase 1 trials, "we still think oral vk-2735 offers strong efficacy with a manageable tolerability profile." Viking reported that 99% of gastrointestinal-related adverse events were mild or moderate. The company also highlighted an exploratory maintenance dosing arm showing weight loss could be maintained at lower doses. The major adverse events included vomiting rates of 20-35% in the three highest dose arms compared to about 10% for placebo, and nausea rates of approximately 58% for patients on treatment versus 48% for placebo. Related articles Viking Therapeutics stock falls 37% on high dropout rate in obesity trial Tesla robotaxi trial impresses, pricing power clear: William Blair Palo Alto Networks gains after strong earnings and Bank of America upgrade
Yahoo
an hour ago
- Yahoo
Ozempic price slashed following Donald Trump's demands - will it impact the UK cost?
Diabetes patients in the US will now be able to purchase Ozempic for half its usual cost. Novo Nordisk, a Danish pharmaceutical company, said on Monday that it would be providing the drug through its direct pharmacy service for $499 (£369) per month, instead of just under $1,000 per month. The drug giant said it had made a deal with healthcare firm GoodRx to make Wegovy, its obesity drug, available at this price in over 70,000 pharmacies nationwide. It comes after Novo Nordisk saw sales plummet last month, after competition ramped up in the US. The company said the profit warning came as a result of 'persistent use' of compounded – or copycat – versions of its drugs, as well as 'slower-than-expected market expansion and competition'. It has faced serious competition from Mounjaro, Eli Lilly's rival weight loss jab, as well as what it described as 'unsafe and unlawful mass compounding' in the market as weight loss and diabetes drugs have soared in popularity. Ozempic and Wegovy both contain glucagon-like peptide-1 (GLP-1). It works by stimulating insulin secretion, which is why it helps patients with type 2 diabetes, but it also signals fullness to the brain. Wegovy only triggers the GLP-1 receptor in the brian but Mounjaro works on both GLP-1 and GIP receptors, which can lead to more weight loss. In March, Novo Nordisk reduced the cost of Wegovy for cash-paying patients, but now people without health insurance will be able to purchase it for this price. Trump's critique The move comes just weeks after President Donald Trump criticised GLP-1 agonists for being more expensive in the US than in other countries, adding that he would 'slash the cost of prescription drugs' by 80 per cent. Last month, Trump wrote to pharmaceutical leaders demanding that they 'negotiate harder with foreign freeloading nations'. He said: 'increased revenues abroad must be repatriated to lower drug prices for American patients and taxpayers'. He's since upped that number, saying he would cut drug prices up to '1,500 percent,' which is mathematically impossible without entering negative numbers. He also said that European nations were 'unfairly shifting the cost burden onto American patients' by using their healthcare services to put pressure on US pharma companies to accept lower prices. Novo Nordisk said that the price cut was unrelated to discussions with the US government. Pfizer CEO Albert Boula has said he and other pharma companies are in talks about making their drugs available at a lower cost. Will it impact the UK cost? In the UK, patients can buy a four-week supply of Ozempic for between £119 and £190 from online pharmacies. Novo Nordisk said it has no plans to rise UK prices, despite pressure from Trump. In a statement, it said it would continue to focus 'on supporting patients, and we are committed to ensuring that our medicines are not only innovative but also accessible and affordable for those who need them most'. However, last week, weight-loss drugmaker Eli Lilly said it would increase UK prices by as much as 170pc due to concerns about unfair pricing. The company said obesity drug Mounjaro would rise in price from Sept 1 in order to address 'pricing inconsistencies compared to other developed countries, including in Europe'. The company's weight-loss jab will cost between £133 and £330 per injection (depending on dosage) in the UK. CheqUp, a weight-loss jab provider, reported that sales of Wegovy increased more than 500pc, following the Eli Lilly announcement.
Yahoo
an hour ago
- Yahoo
knownwell Strengthens Regional Footprint, Opens Second Clinic in the Greater Boston Area
The Company Unveils its Seventh New Weight-Inclusive Care Location in the Last Year, Increasing Patient Population by Nearly 400% BOSTON, August 19, 2025--(BUSINESS WIRE)--knownwell, an in-person and virtual weight-inclusive primary care and metabolic health company that opened its flagship clinic in Needham, Massachusetts in 2023, announces the deepening of its physical presence in the greater Boston area. As the company continues to increase access to weight-inclusive care across the country, the opening of a new clinic will provide additional opportunities for in-person engagement with locally based patients near Woburn, Massachusetts. The news comes on the heels of knownwell opening seven new clinics in the last year, including one in Dallas and six in Chicago, to provide in-person care in the Midwest and South Central regions. It also follows the company's launch of virtual metabolic care to patients in all 50 U.S. states. Today, more than half of adults in Massachusetts are affected by overweight or obesity. In Woburn alone, 1 in 4 adults has obesity. With few options for comprehensive metabolic care in the area, the addition of a new local clinic comes at a pivotal time to support those in need. "Boston has always held a special place in our story – it is where our mission began, and where we proved that weight-inclusive care can change lives," said Brooke Boyarsky Pratt, CEO and Co-Founder of knownwell. "This expansion isn't just about growth; it's about meeting an urgent need in a community that has inspired us from day one. Expanding our footprint here reflects both the significant need and our dedication to delivering accessible, whole-person care to help more people in Massachusetts achieve lasting health." The Woburn clinic arrives amid the demand for GLP-1 medications surging and the cost of treatment continuing to rise, creating new barriers for patients seeking effective, long-term solutions for obesity and overweight. By growing its presence in Massachusetts, the company aims to bridge this gap, delivering treatment that combines clinical, nutritional, and behavioral support to ensure patients receive the full spectrum of care they need to improve their health and quality of life. "When I moved to Massachusetts decades ago, it was to be part of a movement to treat obesity like the chronic disease it is – with science, compassion, and comprehensive care. This expansion in greater Boston is the next chapter in that mission, with knownwell leading the charge," said Chief Medical Officer and Co-Founder of knownwell, Dr. Angela Fitch. "By increasing access to integrated treatment, we're not just helping individuals improve their health but taking meaningful steps toward reducing obesity rates across the country." With the new opening, knownwell will additionally onboard Dr. Giovanna Leddy, President of the New England Obesity Society, as the new Market Medical Director, overseeing both the Woburn and Needham practices. Dr. Leddy serves as the Associate Director of the Social Justice Pathway within the Internal Medicine Residency Program at Beth Israel Deaconess Medical Center and currently practices Obesity Medicine at Atrius Health. She is also a Clinical Instructor in Medicine at Harvard Medical School. knownwell is on a mission to make weight-inclusive healthcare more accessible. It offers full-coverage care, including metabolic health services, comprehensive primary care, nutrition counseling, and behavioral health services online and in person, and accepts insurance. To learn more about knownwell, visit ABOUT KNOWNWELL: knownwell is built for the millions of Americans who have been told that their weight is the problem, regardless of their unique health concerns. Stigmatizing patients does not promote wellness, and in fact, leads to worse health outcomes. knownwell practices evidence-based medicine that supports a patient's unique goals, creating a healthcare home for patients with overweight and obesity. To learn more, visit View source version on Contacts Karalyn HooverSolCommsknownwell@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data